Back HCV Treatment Approved HCV Drugs

Approved HCV Drugs

AASLD 2014: Sofosbuvir + Simeprevir Shows Good Results in Real-World Use

Regimens containing sofosbuvir (Sovaldi) -- including sofosbuvir plus simeprevir (Olysio) -- work well for people with hepatitis C genotype 1 in real-world use, which to date has included some of the patients most urgently in need of treatment at the dawn of the interferon-free era, according to a pair of presentations at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting last week in Boston. Sofosbuvir plus ribavirin alone is highly effective for people with genotype 2.

alt

Read more:

AASLD 2014: AbbVie 3D Regimen and Sofosbuvir/ Ribavirin Show High Cure Rates for HIV/HCV Coinfection

AbbVie's 3D regimen (paritaprevir/ombitasvir/ritonavir plus dasabuvir) with ribavirin for 12 weeks and Gilead Science's sofosbuvir (Sovaldi) plus ribavirin for 24 weeks both produced good sustained virological response rates for most patients with HIV and hepatitis C virus (HCV) coinfection, according to studies presented at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting last week in Boston.

alt

Read more:

AASLD 2014: Sofosbuvir/ Ledipasvir + Ribavirin Highly Effective for People with Decompensated Cirrhosis

An oral regimen of sofosbuvir/ledipasvir (Harvoni) plus ribavirin taken for 12 weeks cured most hepatitis C patients with decompensated cirrhosis, the most advanced stage of liver disease, according to a presentation at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting this week in Boston. Sustained response was associated with improved liver function in most patients.

alt

Read more:

AASLD 2014: Grazoprevir/ Elbasvir Combo Shows High Cure Rates, Including Cirrhotics and Coinfected

An all-oral regimen of grazoprevir (MK-5172) and elbasvir (MK-8742), taken with or without ribavirin for 12 weeks, demonstrated high sustained virological response rates for treatment-naive and treatment-experienced genotype 1 hepatitis C patients, including people with liver cirrhosis and HIV/HCV coinfection, according to research presented at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting this week in Boston and published simultaeously in The Lancet. However, pushing treatment duration with this combination plus sofosbuvir down to 4 or 6 weeks raised the risk of treatment failure.

alt

Read more:

AASLD 2014: Sofosbuvir/Ledipasvir and AbbVie 3D Cure Most People with HCV Genotype 4

Sofosbuvir/ledipasvir (Harvoni) without ribavirin and AbbVie's 3D regimen (paritaprevir/ombitasvir plus dasabuvir) both produced high sustained virological response rates for patients with hepatitis C virus (HCV) genotype 4, according to a pair of studies presented at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting this week in Boston.

alt

Read more: